zalcman mesothelioma

Web results
Bevacizumab for newly diagnosed pleural mesothelioma ... - The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstractby G Zalcman - ‎2016 - ‎Cited by 221 - ‎Related articlesDec 21, 2015 - Prof Gérard Zalcman, MD .... Malignant pleural mesothelioma is an aggressive cancer with poor ... Prognostic factors for mesothelioma.
‎Summary · ‎References
Bevacizumab for newly diagnosed pleural mesothelioma in the ... - NCBI
https://www.ncbi.nlm.nih.gov/pubmed/26719230


by G Zalcman - ‎2016 - ‎Cited by 221 - ‎Related articlesDec 21, 2015 - Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma ...Zalcman G(1), Mazieres J(2), Margery J(3), Greillier L(4), ...
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi ...
ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA8507by A Scherpereel - ‎2017 - ‎Cited by 20 - ‎Related articlesSecond- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleuralmesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 ...

ESMO 2017 Press Release: Combination Immunotherapy in Second ...
https://www.esmo.org/.../Combination-Immunotherapy-in-Second-third-Line-Extends...


Sep 10, 2017 - Malignant pleural mesothelioma (MPM) is a rare disease usually caused ... GérardZalcman during Proffered Paper session 'Mesothelioma and ...

French Oncologists Upgrade Mesothelioma Standard of Care
https://www.asbestos.com/news/2017/.../france-upgrades-bevacizumab-mesothelioma/


Nov 20, 2017 - “This is a major advancement for the care of mesothelioma patients,” Dr. GerardZalcman, head of thoracic oncology at Bichat-Claude Bernard ...
Immunotherapy Impact Extends to Mesothelioma - OncLive
https://www.onclive.com/web.../immunotherapy-impact-extends-to-mesothelioma


Nov 9, 2017 - Gerard Zalcman, MD, discusses the promise of immunotherapy in patients withmesothelioma.
Malignant Pleural Mesothelioma: IFCT-GFPC-0701 MAPS Phase III ...
https://am.asco.org › Daily News



May 31, 2015 - [image:1:right] Malignant pleural mesothelioma (MPM) is a locoregional ... GérardZalcman, MD, PhD, of Caen University Hospital, France, ...
Immunotherapy in relapsed mesothelioma | Immunotherapy
https://www.futuremedicine.com/doi/full/10.2217/imt-2017-0144by S Brosseau - ‎2018 - ‎Cited by 2 - ‎Related articlesDec 20, 2017 - Solenn Brosseau; ,; Xavier Dhalluin; ,; Gerard Zalcman; &; Arnaud ... Malignant pleuralmesothelioma (MPM) is a rare but aggressive ...
[PDF]
Bevacizumab for newly diagnosed pleural mesothelioma in the ...
https://www.clydesideactiononasbestos.org.uk/.../Meso-bevacisumab-20151-s2.0-S01...


by G Zalcman - ‎2015 - ‎Cited by 221 - ‎Related articlesDec 21, 2015 - the Mesothelioma Avastin Cisplatin Pemetrexed Study ... Gérard Zalcman, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse ...
Bevacizumab for Newly Diagnosed Malignant Pleural Mesothelioma
https://www.jwatch.org/.../bevacizumab-newly-diagnosed-malignant-pleural-mesotheli...


Jan 21, 2016 - Malignant pleural mesothelioma (MPM) is a challenging disease with few treatment options. ... Anne S. Tsao, MD reviewing Zalcman G et al.




Page navigation
1 2 3 4 5 6 7 8 9 10 Next